H.C. Wainwright lowered the firm’s price target on Citius Pharmaceuticals (CTXR) to $4 from $100 and keeps a Buy rating on the shares following the one-for-25 reverse stock split. Citius has potential to have two therapies, Mino-Lok and Lymphir, in commercialization by first half 2026, which is underappreciated at current share levels, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTXR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue